Tags

Type your tag names separated by a space and hit enter

Statin use and risk of bladder cancer: a meta-analysis.
Cancer Causes Control. 2013 Apr; 24(4):769-76.CC

Abstract

PURPOSE

Emerging evidence suggests that statins may decrease the risk of cancers. However, available evidence on bladder cancer is conflicting. To quantify the association between statin use and risk of bladder cancer, we performed a detailed meta-analysis of published studies regarding this subject.

METHODS

A literature search was carried out using MEDLINE, EMBASE, and OVID databases between January 1966 and October 2012. Before meta-analysis, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Fixed- and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95 % confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses, sensitivity analysis, and cumulative meta-analysis were also performed.

RESULTS

A total of 13 (three RCTs, five cohort, and five case-control) studies contributed to the analysis. There was heterogeneity among the studies, but no publication bias. Pooled results indicated a nonsignificant increase in total bladder cancer risk among all statin users [RR = 1.07, 95 % CI (0.95, 1.21)]. Long-term statin use did not significantly affect the risk of total bladder cancer [RR = 1.21, 95 % CI (0.92, 1.59)]. In our subgroup analyses, the results were not substantially affected by study design, region, and confounder adjustment. Furthermore, sensitivity analysis confirmed the stability of the results.

CONCLUSIONS

The findings of this meta-analysis suggested that there was no association between statin use and risk of bladder cancer. More studies, especially RCTs, are needed to confirm this association.

Authors+Show Affiliations

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, 301 Yanchang Road, Shanghai, 200072, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

23361339

Citation

Zhang, Xiao-long, et al. "Statin Use and Risk of Bladder Cancer: a Meta-analysis." Cancer Causes & Control : CCC, vol. 24, no. 4, 2013, pp. 769-76.
Zhang XL, Geng J, Zhang XP, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control. 2013;24(4):769-76.
Zhang, X. L., Geng, J., Zhang, X. P., Peng, B., Che, J. P., Yan, Y., Wang, G. C., Xia, S. Q., Wu, Y., & Zheng, J. H. (2013). Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes & Control : CCC, 24(4), 769-76. https://doi.org/10.1007/s10552-013-0159-3
Zhang XL, et al. Statin Use and Risk of Bladder Cancer: a Meta-analysis. Cancer Causes Control. 2013;24(4):769-76. PubMed PMID: 23361339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statin use and risk of bladder cancer: a meta-analysis. AU - Zhang,Xiao-long, AU - Geng,Jiang, AU - Zhang,Xiao-peng, AU - Peng,Bo, AU - Che,Jian-ping, AU - Yan,Yang, AU - Wang,Guang-chun, AU - Xia,Sheng-qiang, AU - Wu,Yan, AU - Zheng,Jun-hua, Y1 - 2013/01/30/ PY - 2012/10/27/received PY - 2013/01/19/accepted PY - 2013/1/31/entrez PY - 2013/1/31/pubmed PY - 2013/9/13/medline SP - 769 EP - 76 JF - Cancer causes & control : CCC JO - Cancer Causes Control VL - 24 IS - 4 N2 - PURPOSE: Emerging evidence suggests that statins may decrease the risk of cancers. However, available evidence on bladder cancer is conflicting. To quantify the association between statin use and risk of bladder cancer, we performed a detailed meta-analysis of published studies regarding this subject. METHODS: A literature search was carried out using MEDLINE, EMBASE, and OVID databases between January 1966 and October 2012. Before meta-analysis, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Fixed- and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95 % confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses, sensitivity analysis, and cumulative meta-analysis were also performed. RESULTS: A total of 13 (three RCTs, five cohort, and five case-control) studies contributed to the analysis. There was heterogeneity among the studies, but no publication bias. Pooled results indicated a nonsignificant increase in total bladder cancer risk among all statin users [RR = 1.07, 95 % CI (0.95, 1.21)]. Long-term statin use did not significantly affect the risk of total bladder cancer [RR = 1.21, 95 % CI (0.92, 1.59)]. In our subgroup analyses, the results were not substantially affected by study design, region, and confounder adjustment. Furthermore, sensitivity analysis confirmed the stability of the results. CONCLUSIONS: The findings of this meta-analysis suggested that there was no association between statin use and risk of bladder cancer. More studies, especially RCTs, are needed to confirm this association. SN - 1573-7225 UR - https://www.unboundmedicine.com/medline/citation/23361339/Statin_use_and_risk_of_bladder_cancer:_a_meta_analysis_ L2 - https://doi.org/10.1007/s10552-013-0159-3 DB - PRIME DP - Unbound Medicine ER -